Q BioMed ($QBIO)Has anyone done any research on Q BioMed ($QBIO)? If so, your thoughts and finds would be appreciated. Thank you.
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
Has anyone done any research on Q BioMed ($QBIO)? If so, your thoughts and finds would be appreciated. Thank you.
My findings thus far:
Q BioMed Inc ($QBIO) bills itself as a company that operates as a biomedical acceleration and development company in the United States.
The company focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. Its primary target indication is for a therapeutic eye-drop for the treatment of glaucoma in adults. The companyโs lead candidate is MAN-01.
The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was founded in 2013 and is based in New York, New York.
QBIO is a biomedical acceleration and development company. The Company is focused on licensing and acquiring biomedical assets across the healthcare spectrum.
Hi gmw,
I just found this recent press release dated 6/15/17. This talks about treating liver cancer, not glaucoma
Q BioMed Inc. Finalizes License Agreement With Oklahoma Medical Research Foundation and the Rajiv Gandhi Centre for Biotechnology for Novel Liver Cancer Treatment
NEW YORK, June 15, 2017 /PRNewswire/ —
Q BioMed Inc. (OTCQB: QBIO), is very pleased to announce their entry into a final license agreement with The Oklahoma Medical Research Foundation (OMRF) and the Rajiv Gandhi Centre for Biotechnology (RGCB). Under the agreement QBioMed has the global exclusive rights to develop and market a novel chemotherapeutic drug to treat liver cancer.
The compound was isolated and characterized from the leaves of Solanum nigrum Linn, or black nightshade, a plant widely used in traditional medicine.
In animal models, the compound, called uttrocide B, was shown to be 10 times more cytotoxic to HepG2 liver cancer cells than the only drug currently on the market for the condition.
“Our ultimate goal is to use uttrocide B as a chemotherapeutic against liver cancer, which has very few therapeutic options,” said Q BioMed, Inc., CEO Denis Corin.
RGCB researchers identified the therapeutic effect of the compound and then entered into collaboration with OMRF to further develop and commercialize it. In animal models, uttrocide B was shown to be more potent than the currently available drug for the disease and caused no noticeable side effects.
“We are excited at the prospect of developing a drug that could address a significant unmet medical need and benefit patients”, said Dr. M.R.Pillai, Director of RGCB.
Liver cancer is the second most common cause of cancer deaths worldwide, according to the Centers for Disease Control and Prevention, and claims approximately 750,000 lives each year. The American Cancer Society estimates that 39,000 people in the U.S. will be diagnosed with primary liver cancer in 2017 and that 27,000 will die from the disease this year.
“This is truly an unmet need in liver cancer,” said OMRF Vice President of Technology Ventures, Manu Nair. “To find a plant-based treatment for a condition like liver cancer can open the door to a wide variety of other natural products for treating human disease.”
Please visit http://www.qbiomed.com for more information and sign up to receive regular updates. Follow us on Twitter @QBioMed.